Changing the future of Oncology.
About Sutro Biopharma
Sutro Biopharma is a clinical stage company pioneering a compelling and unique way of discovering, developing and manufacturing therapeutics. Our focus is aimed primarily on next generation cancer and autoimmune therapeutics — antibody conjugates, bispecific antibodies and cytokine derivatives. Unconstrained by traditional methods of cell-based discovery, we can design and develop targeted medicines by innovating outside the constraints of the cell.
Precision protein engineering generates superior molecules
3 product candidates in the clinic as a result of research innovations
Great people making excellence happen, every day!
Our technology enables us to iteratively discover and test molecules in a rapid cycle of weeks rather than months, to rapidly identify optimal molecules designed for safety and potency.
To download the World ADC presentation by Arturo Molina, MD, MS, Chief Medical Officer, CLICK HERE To download the World ADC presentation by Trevor Hallam, Ph.D., Chief Scientific Officer, CLICK HERE To download the World ADC presentation by Shabbir Anik, Ph.D.,...
To download the presentation, Click Here
STRO-002 Shows Early Efficacy, Safety in Heavily Pretreated Epithelial Ovarian Cancer – OncLive September 2020
The novel anti-folate receptor alpha antibody-drug conjugate STRO-002 demonstrated encouraging efficacy with a tolerable safety profile in patients with advanced platinum-resistant or refractory epithelial ovarian cancer. The novel anti-folate receptor alpha (FolRα)...